Sep 12, 2022 / 02:30PM GMT
Matthew Kelsey Harrison - Morgan Stanley, Research Division - Executive Director
Great. Well, good morning, everybody. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Very pleased to have Editas with us for the next session. Just briefly, before we get started, I need to read a quick disclosure statement. Please note that all important disclosures, including personal holdings disclosures are available at the Morgan Stanley public website at morganstanley.com/research disclosures. Now with that excitement out of the way, we can get down to the real business. So really pleased to have the team here with us.
Questions and Answers:
Matthew Kelsey Harrison - Morgan Stanley, Research Division - Executive DirectorI thought maybe a nice place to start is just, there's so much innovation in gene editing going on. And I think from an investor standpoint, there's a lot of different modalities now in gene editing. So can you talk a little bit about how you think about your underlying technology